| abstract |
Methods and drugs are provided for treating and inhibiting the interaction of a terminal glycation end product receptor (RAGE) and its ligand using natural or synthetic sulfated polysaccharides, preferably 2-O desulfated heparin. The drug is preferably administered by intravenous aerosolization, nasally, intraarticularly, intrathecally, subcutaneously, topically or orally. The drugs are useful for treating a variety of conditions including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis. |